摘要
目的 评价文拉法辛缓释剂(怡诺思)与氯米帕明(安拿芬尼)治疗门诊抑郁症的临床疗 效和安全性。方法 将80例抑郁症门诊患者依就诊顺序随机分为两组,分别给予文拉法辛缓释剂(n= 42)和氯米帕明(n=38)治疗,在2周内逐步增高剂量至150mg/d,在治疗前后用汉密尔顿抑郁量表 (HAMD)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和不良反应。结果 文拉法辛 缓释剂与氯米帕明对抑郁症的治疗疗效相近,但前者起效更快,不良反应少于后者。结论 文拉法辛 缓释剂是安全、有效、依从性好、不良反应较少的新一代抗抑郁药。
Objective: To compare clinical efficacy and safety between venlafaxine-XR and clomipramine in the treatment of depression. Methods: The 80 outpatients meeting with criteria of depression in CCMD-Ⅲ were received either venlafaxine or clomipramine for 6 weeks, at a dose titrated from 50 mg to a maximum of 150 mg/day during the first 10 days of treatment. Effects and adverse events were evaluated with HAMD、HAMA and TESS before and after the treatment. Results: It was found that efficacy of venlafaxine-XR was similar to clomipramine, however venlafaxine-XR took effect more quickly and its adverse events were less than clomipramine. Conclusion: Venlafaxine-XR is an effective and safe antidepressant.
出处
《上海精神医学》
北大核心
2004年第6期350-352,共3页
Shanghai Archives of Psychiatry
